All News

FDA.jpg (keep)

FDA Advisors Split on Avacopan for Vasculitis

d MedPage Today

Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Read Article
blood, level, numbers, data, calculation

Higher Hydroxychloroquine Blood Levels Reduces Thrombosis Risk in Lupus

d Jack Cush, MD

Petri and colleagues have published that measuring hydroxychloroquine (HCQ) blood levels can be useful in systemic lupus erythematosus (SLE), as low levels are associated with an increased thrombotic risk in SLE.

Read Article
ANCA, vasculitis, test

Avacopan for ANCA Vasculitis Goes in Front of the FDA

d MedPage Today

An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.

Read Article
RheumNow Podcast square

RheumNow Podcast – Falling or Falling in Love?

d Jack Cush, MD

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Read Article
News Feature: Higher Hydroxychloroquine Blood Levels Reduces Thrombosis Risk in Lupus Petri and colleagues have published that measuring HCQ blood levels is useful in SLE patients as low levels are associated with thrombosis in SLE. https://t.co/jAXUJoM2Pa https://t.co/h8KonZRnX8

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective cohort study of 419 gout patients compared low dose 0.6 mg qd (LD) vs regular 0.6 mg bid (RD) colchicine as prophylaxis when starting urate lowering therapy. Rate of gout flares were roughly equal (LD 14.3% vs RD 11.3%) https://t.co/8G6siQlHbI

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Childhood Lupus May Hamper Adult Careers Long-term outcomes of kids with cSLE are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood. https://t.co/RQc4JD3BIt https://t.co/y5LboAUsw3

Links:

Dr. John Cush RheumNow ( View Tweet)
281,264 people vax w/ Oxford-AstraZeneca COVID vaccine - had 59 VTEs (30 expected; 2 fold incr.) +Higher than expected cerebral VTE seen (excess of 2.5 100K Vax). Thrombocytopenia/coagulation disorders were rare but not in excess. https://t.co/m3cjqkzHSW

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of the epidemiology of #RA shows average point and period prevalence of RA to be 51 to 56 per 10,000, respectively. Higher with rheumatologist diagnosis (81 per 10,000). https://t.co/5AeNdmBLJO

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Unique Oral Microbiome in Early and Pre-Clinical RA An oral microbiome study of rheumatoid arthritis (RA) patients suggests that periodontal condition in patients with early rheumatoid arthritis (ERA) and individuals at risk of RA. https://t.co/r3kT52MByC https://t.co/MocZ6PXZzA

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you listened to the latest RheumNow podcast? Falling or Falling in Love https://t.co/SmPCqKpXLY https://t.co/LQSsGJCY9u

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Avacopan for ANCA Vasculitis Goes in Front of the FDA An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for ANCA-associated vasculitis. https://t.co/66NSjbkE8Q https://t.co/9cR2lBASjz

Links:

Dr. John Cush RheumNow ( View Tweet)
#LupusAwarenessMonth Dr. Kathryn Dao - Risk of Hydroxychloroquine Retinal Toxicity From ACR 2020 https://t.co/7BCVvMOm0T https://t.co/PhHubO7rxG

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: ARTIC REWIND - Don't Half DMARD Therapy https://t.co/mZFehDM9nf https://t.co/QQ8IhMYUjk

Links:

Dr. John Cush RheumNow ( View Tweet)
#LupusAwarenessMonth Dr. Janet Pope - Belimumab in SLE nephritis From ACR 2020 https://t.co/ZoMslbX5dF https://t.co/xnKXXRJ6wE

Links:

Dr. John Cush RheumNow ( View Tweet)
#LupusAwarenessMonth Dr. Michelle Petri - Best Practices in Testing for Antiphospholipid Syndrome (LAC wins) From ACR 2020 https://t.co/IyeRDzw4BC https://t.co/nSkauHf29T

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast alert! Falling or Falling in Love (5.7.2021) Dr Jack Cush reviews the best journal articles of the week from RheumNow https://t.co/HyAPN2rM3L https://t.co/C5XtqthO8I

Links:

Dr. John Cush RheumNow ( View Tweet)
May is also arthritis awareness month! Why we love Rheumatology Fellows https://t.co/rNVjZZr9l4 #ArthritisAwarenessMonth

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Drug Monitoring Ineffective with Infliximab Treatment A randomized trial compared TDM to no TDM in patients receiving infliximab for chronic IMIDs and found that TDM did not increase the odds of achieving remission. https://t.co/AVcX4EXY0l https://t.co/RlDij6ln61

Links:

Dr. John Cush RheumNow ( View Tweet)
Falls are not uncommon in #RA patients; significant risk factors for falls include being elderly, un-married, higher pain scores, reported dizziness taking psychotropic medications and having lower HRQoL scores https://t.co/a8qA7n68q5

Links:

Dr. John Cush RheumNow ( View Tweet)

×